Acceso usuarios
* Simeprevir (Olysio) is a new protease inhibitor approved for the treatment of adults with hepatitis C viral infection. Simeprevir should be used as part of a combination therapy treatment plan.
* Genotype 1a hepatitis C virus with the NS3 Q80K polymorphism will not respond well to simeprevir therapy.
* Common adverse effects are rash (including photosensitivity), pruritis, and nausea.
